SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Curaleaf Laboratories and Sanity Group Announce Partnership to Advance Medical Cannabis Innovation in the UK

    By

    Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products. 

    The partnership brings together Curaleaf Laboratories’ established manufacturing, quality, and commercial capabilities with Sanity Group’s international expertise in cannabinoid-based therapeutics. Together, the companies will collaborate to develop, manufacture, and commercialise innovative medical cannabis products tailored to the needs of UK patients and healthcare professionals.

    Under the agreement, Curaleaf Laboratories will leverage its MHRA-approved infrastructure and compliance framework to support the introduction of new formulations, while Sanity Group will contribute its pharmaceutical know-how, intellectual property and experience in building clinically relevant cannabinoid products across global markets.

    Richard Hodgson, Managing Director of Curaleaf Laboratories: “This partnership represents a significant step forward in our mission to deliver consistent, pharmaceutical-grade medical cannabis products to patients in the UK. By working with Sanity Group, we are combining complementary strengths to accelerate innovation while maintaining the highest standards of quality, safety, and regulatory compliance.”

    Finn Hänsel, Founder and Managing Director of Sanity Group: “The UK is a key strategic market for medical cannabis. Partnering with Curaleaf Laboratories allows us to translate our capabilities into scalable, compliant products that can make a meaningful difference for patients and prescribing clinicians.”

    This partnership underscores the continued maturation of the UK medical cannabis market and reflects a shared vision to set new benchmarks for quality, innovation, and patient-centric care.

    The first Sanity Group products manufactured under this partnership will be available on prescription by clinicians listed on the UK Specialist Register from Q1 2026.

    If you are an interested healthcare professional seeking information on prescribing or ordering, please contact us at info@curaleaflaboratories.co.uk

    Patients seeking information from their dispensing pharmacy may visit Curaleaf Pharmacy if applicable. Treatment decisions should be made in consultation with a qualified healthcare professional.

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    BusinessOfCannabis

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free